The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 04, 2021

Filed:

Apr. 16, 2018
Applicants:

Arizona Board of Regents on Behalf of the University of Arizona, Tucson, AZ (US);

The United States of America As Represented BY the Department of Veterans Affairs, Washington, DC (US);

Inventors:

Joe G. N. Garcia, Tucson, AZ (US);

Louise Hecker, Tucson, AZ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/4545 (2006.01); A61P 11/00 (2006.01); A61K 9/00 (2006.01); A61K 31/4439 (2006.01); A61K 31/444 (2006.01); C07K 16/40 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4545 (2013.01); A61K 9/0019 (2013.01); A61K 31/444 (2013.01); A61K 31/4439 (2013.01); A61P 11/00 (2018.01); C07K 16/40 (2013.01); C07K 2317/55 (2013.01); C07K 2317/76 (2013.01);
Abstract

Inhibition of the expression and/or function of nicotinamide phosphoribosyltransferase (NAMPT) can reduce, prevent or reverse the pathophysiological vascular changes associated with the onset and progression of Pulmonary Fibrosis. Compositions and methods to inhibit the expression and function of NAMPT for treating and preventing Pulmonary Fibrosis in a subject in need are provided. The compositions and methods are useful for the modulation of pathophysiological processes that contribute to the development and progression of Pulmonary Fibrosis by reducing lung inflammation, aberrant myofibroblast accumulation and deposition of collagen in fibrotic foci.


Find Patent Forward Citations

Loading…